The health-tech newsletter for insiders and operators

Where 50k clinicians, entrepreneurs, executives, investors and operators get weekly insights
on the intersection of healthcare and technology.

Roundup

AI drug discovery’s expensive reality

Christina Farr, +2

•

May 30, 2026

Venture Capital

Because of AI, the new startup flex will be how little VC money you raise

Christina Farr, +1

•

May 28, 2026

Patient-Facing AI in Healthcare

Oura’s IPO Could Become a Watershed Moment for Women’s Health

Christina Farr, +2

•

May 27, 2026

Roundup

The Food and Drug Administration in free fall

Christina Farr, +2

•

May 20, 2026

Healthtech

AI startups see opportunity in the public sector

Ruth Reader

•

May 18, 2026

Digital Health

Review: Our first in a new series evaluating the latest medical AI studies

Dr. Shantanu Nundy

•

May 16, 2026

Consumer Health

Why CFOs are freaking out about healthcare costs in 2026

Christina Farr

•

May 14, 2026

Roundup

Healthcare adopts the New Media playbook by hiring in-house journalists

Christina Farr, +3

•

May 11, 2026

Patient-Facing AI in Healthcare

Dr. Eric Topol: Medical AI is facing a dangerous 'paradox'

Ruth Reader

•

May 7, 2026

Patient Acquisition

Former FDA Deputy weighs in on the push into ‘real-time clinical trials’

Ruth Reader

•

May 5, 2026

The health-tech newsletter for insiders and operators

Where 50k clinicians, entrepreneurs, executives, investors and operators get weekly insights on the intersection of healthcare and technology.

AI drug discovery’s expensive reality

Because of AI, the new startup flex will be how little VC money you raise

Oura’s IPO Could Become a Watershed Moment for Women’s Health

The Food and Drug Administration in free fall

AI startups see opportunity in the public sector

Review: Our first in a new series evaluating the latest medical AI studies

Why CFOs are freaking out about healthcare costs in 2026

Healthcare adopts the New Media playbook by hiring in-house journalists

Dr. Eric Topol: Medical AI is facing a dangerous 'paradox'

Former FDA Deputy weighs in on the push into ‘real-time clinical trials’

Where 50k clinicians, entrepreneurs, executives, investors and operators get weekly insights
on the intersection of healthcare and technology.